Target-Specific Oral Anticoagulation: Focus on Venous Thromboembolism and Atrial Fibrillation
 
Release Date: February 23, 2015
Last Reviewed: February 17, 2015
Expiration Date: February 23, 2016
Time to Complete Activity:  2.0 hours

*This activity expired for credit on February 23, 2016 and is no longer available for credit
 
This activity is provided by the Icahn School of Medicine at Mount Sinai.  

Faculty
Jonathan L. Halperin, MD, FACC, FAHA (Course Director)
Robert and Harriet Heilbrunn Professor of Medicine (Cardiology)
Icahn School of Medicine at Mount Sinai
New York, NY
 
Gerald V. Naccarelli, MD, FACC, FAHA, FHRS (Chair)
Bernard Trabin Chair in Cardiology
Professor of Medicine
Chief, Division of Cardiology
Penn State University College of Medicine
Heart and Vascular Institute
Hershey, PA
 
Mark J. Alberts, MD, FAHA
Vice-Chair, Clinical Affairs
Professor of Neurology
Department of Neurology and Neurotherapeutics
UT Southwestern Medical Center
Dallas, TX
 
Samuel Z. Goldhaber, MD
Professor of Medicine
Harvard Medical School
Director, Thrombosis Research Group
Brigham and Women’s Hospital
Boston, MA
 
Sarah A. Spinler, PharmD, FCCP, FCPP, FAHA, FASHP, AACC, BCPS AQ–Cardiology
Professor of Clinical Pharmacy
Philadelphia College of Pharmacy
University of the Sciences
Philadelphia, PA
 
Peer Reviewer
Sameer Bansilal, MD
Assistant Professor of Medicine (Cardiology)
Icahn School of Medicine at Mount Sinai
New York, NY 
 
Target Audience
This activity has been designed for specialists in cardiology, interventional cardiology, anticoagulation, hospital medicine, internal medicine, pulmonary medicine, emergency medicine, and primary care, as well as nurse practitioners, physician assistants, and clinical pharmacists, as well as other healthcare providers interested in thrombosis management.  
 
Statement of Need
Despite the availability of non-vitamin K antagonist oral anticoagulants (NOACs) in the last few years, many at-risk patients do not receive appropriate anticoagulation. During this CE-certified program, expert faculty use a case-based approach to illustrate how the validated risk assessment tools and data from clinical trials can be applied to selecting and managing an appropriate oral anticoagulant for individual patients.
 
Educational Objectives
At the conclusion of this activity, participants should be better able to:
  • Develop strategies to identify patients who require stroke prevention based on an understanding of the pathophysiology of NVAF.
  • Apply current clinical practice guidelines of VTE prevention and treatment.
  • Select an appropriate OAC based on important patient characteristics and efficacy and safety data of VKAs.
Agenda
  • Welcome and Introductions
  • Individualizing Oral Anticoagulant Therapy
  • Rapid-fire Questions, Clinical Challenge Case Vignettes
  • Patient Case Challenge 1: AF and Stroke and ACS
  • Patient Case Challenge 2: Venous Thromboembolism
  • Patient Case Challenge 3: AF with Comorbidities and Drug Interactions
  • Q&A
Accreditation
The Icahn School of Medicine at Mount Sinai is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
 
Credit Designation
The Icahn School of Medicine at Mount Sinai designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
Pharmacist Continuing Education
Accreditation Statement
Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.



This activity is jointly provided by Global Education Group and Paradigm Medical Communications, LLC. 

 

 

Credit Designation Statement
Global Education Group designates this continuing education activity for 2.0 contact hours (0.2 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – 0530-0999-14-202-H01-P)
 
This is a knowledge-based activity.
 
Physician Assistant Continuing Education
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 2.0 hours of Category 1 credit for completing this program.
 
Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.  Individuals are responsible for checking with the AANPCP for further guidelines.
 
Disclosure of Commercial Support
This activity is supported by independent educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Daiichi Sankyo, Inc.
 
Instructions for Participation
To receive a CE certificate of participation, participants must:
  • Follow instructions to register or log in with your professional information and complete the pretest.
  • View the online activity in its entirety.
  • Complete and submit the online posttest and evaluation. You must answer 70% of the posttest questions correctly to earn credit. You will have unlimited opportunities to successfully complete the posttest.
A certificate of participation will be available for download/printing immediately following your successful completion of the posttest and evaluation.
 
Please note:to claim CPE credit, please make sure you include your date of birth and NABP number. All credit information will be uploaded into CPE Monitor within 30 days.

For questions regarding credit, contact the Paradigm CME Department at (845) 398-5949.
 
There is no fee required for participation in this activity.

Hardware/Software Requirements
This certified CME activity is designed using HTML5 video. As you navigate the video using the supplied controls, the slides will sync to the speaker.
 
Supported Browsers:
For Desktops (Windows/Mac)
Internet Explorer 9 or higher, Firefox 28 or higher, Safari 5.1 or higher, Google Chrome 31 or higher, Opera 21 or higher
 
For Tablets (iPad/Android/Surface)
iOS Safari 4 or higher, Android 2.3 or higher, IE Mobile 10 or higher

Disclosure and Resolution of Conflict of Interest
The Icahn School of Medicine at Mount Sinai, Global Education Group (Global) and Paradigm Medical Communications, LLC (Paradigm) require instructors, planners, managers, and other individuals, and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity.  All identified conflicts of interest are thoroughly vetted by the Icahn School of Medicine at Mount Sinai, Global, and Paradigm for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. 
 
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
 
Name of Faculty or Presenter
Reported Financial Relationship
Jonathan L. Halperin, MD, FACC, FAHA (Course Director)
 
Advisory Board: Bayer HealthCare AG; Boehringer Ingelheim;
 Daiichi-Sankyo Company, Ltd.; Johnson & Johnson; Ortho-McNeil-Janssen
Pharmaceuticals, Inc.; Pfizer, Inc.; Sanofi-Aventis U.S.
Retained Consultant: AstraZeneca; Biotronik; Boehringer Ingelheim;
Boston Scientific Corporation;
Janssen Pharmaceuticals, Inc.; Medtronic, Inc.; Pfizer, Inc.; Sanofi-Aventis U.S.
 
Gerald V. Naccarelli, MD, FACC, FAHA, FHRS (Chair)
 
Retained Consultant: Biosense-Webster, Inc.; Boehringer Ingelheim;
Bristol-Myers-Squibb Company;
Daiichi-Sankyo Company, Ltd.; Glaxo-Smith-Kline; Janssen Pharmaceuticals, Inc.;
 Otsuka Pharmaceutical Co., Ltd.; Pfizer, Inc.; Sanofi Aventis U.S.; Xention
Mark J. Alberts, MD, FAHA
 
Retained Consultant: Boehringer Ingelheim; Bristol-Myers-Squibb Company;
Chiesi USA, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.;
Merck & Co. Inc.; Pfizer, Inc.  
Samuel Z. Goldhaber, MD
 
Grant/Research Support: Bristol-Myers-Squibb Company;
Daiichi Sankyo Company, Inc.; BTG; NHLBI; Thrombosis Research
Institute (London, UK)
Retained Consultant: Ariad Pharmaceuticals, Inc.; Bayer;
Boehringer Ingelheim; Bristol-Myers-Squibb Company; Daiichi-Sankyo Company, Ltd.;
Genentech, Inc.; Janssen, Pharmaceuticals, Inc.; Merck & Co., Inc.; Pfizer, Inc.;
Portola Pharmaceuticals, Inc.  
 
Sarah A. Spinler, PharmD, FCCP, FCPP, FAHA, FASHP, AACC, BCPS AQ–Cardiology
No financial relationships to disclose.
 
 
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
 
Name of Planner or Manager
Reported Financial Relationship
Ashley Marostica, RN, MSN
No financial relationships to disclose.
Amanda Glazer, PhD
No financial relationships to disclose.
Amanda Jamrogiewicz
No financial relationships to disclose.
Laura Gilsdorf
No financial relationships to disclose.
Kelly Enders
No financial relationships to disclose.
 
Paradigm Medical Communications, LLC staff members have no financial relationships to disclose.
 
The Icahn School of Medicine at Mount Sinai staff members have no financial relationships to disclose.
 
Independent peer reviewer has no financial relationships to disclose.
 
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Icahn School of Medicine at Mount Sinai,Global, and Paradigm do not recommend the use of any agent outside of the labeled indications. 
 
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
 
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
 
Terms of Use and Privacy Policy
Disclaimer
The materials provided for this activity are for informational purposes only, and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. Any views or opinions presented are solely those of the Faculty, and do not necessarily represent those of the Icahn School of Medicine at Mount Sinai, Global, or Paradigm. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, bythe Icahn School of Medicine at Mount Sinai, Global, or Paradigm. The Icahn School of Medicine at Mount Sinai, Global, and Paradigm accept no liability for the content referenced in this activity.
 
Privacy policy
The Icahn School of Medicine at Mount Sinai, Global, and Paradigm arecommitted to protecting the privacy of those who participate in the activities (herein referred to as "website") located at www.paradigmmc.com. The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.
 
Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.
 
Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CE activity. All evaluative information submitted is collected and retained, and used by the Icahn School of Medicine at Mount Sinai, Global and Paradigm to continuously improve the learning experience.
 
The Icahn School of Medicine at Mount Sinai, Global, and Paradigm do not transfer, sell, or share personal information with outside parties.The Icahn School of Medicine at Mount Sinai, Global, and Paradigm will not otherwise disclose personal information unless required to in a legal process. The Icahn School of Medicine at Mount Sinai, Global, and Paradigm staff members review individual test results to the extent necessary to record and track participants’ credits.
 
Contact Us
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity @ cme@mssm.edu.  
 
Global Contact Information: For information about the ACPE accreditation of this program, please contact Global at 303-395-1782 or inquire@globaleducationgroup.com.

Technical Support: If you have any technical problems or playback issues, please click on the Technical Support button on the left of the screen or call (845) 398-5100 or email us at contactus@paradigmmc.com
 
© 2015 Paradigm Medical Communications, LLC, except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.
 
Please Note: This symposium was recorded prior to the approval of edoxaban, which occurred on January 8, 2015. Please be aware that the slide content has been updated in several instances to reflect this change.